Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan

Yasuoka, Shotaro; Yuasa, Takeshi; Ogawa, Masahiro; Komai, Yoshinobu; Numao, Noboru; Yamamoto, Shinya; Kondo, Yukihiro; Yonese, Junji

doi:10.21873/anticanres.13784

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 23 included studies demonstrated the potency of PSA as biomarker on treatment with various therapies for prostate cancer. PSA > 100 ng/ml was found to be significant predictor for shorter OS in two studies [ 48 – 50 ] while PSA decline of > 50 or > 30% was observed to be significant in another study [ 49 ]. Higher hemoglobin level before treatment with cabazitaxel (p = 0.024) and a lower alkaline phosphatase (AP) level at the start of treatment (p = 0.034) resulted in a higher chance of PSA response in another study [ 50 ].…”

Section: Resultsmentioning

confidence: 99%

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

et al. 2020

View full text Add to dashboard Cite

Background: Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current biomarkers is difficult and often results in unnecessary invasive procedures as well as over-diagnosis and over-treatment. There are a number of prognostic biomarkers for CRPC, but there are no validated predictive biomarkers to guide in clinical decision-making. Specific biomarkers are needed that enable to understand the natural history and complex biology of this heterogeneous malignancy, identify early response to treatment outcomes and to identify the population of men most likely to benefit from the treatment. In this systematic review, we discuss the existing literature for the role of biomarkers in CRPC and how they aid in the prognosis, treatment selection and survival outcomes. Methods: We performed a literature search on PubMed and EMBASE databases from January 2015 through February 2020 in accordance to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Articles were assessed to identify relevant observational studies and randomized controlled trials regarding biomarkers which aid in identifying progression to mCRPC as well as predictive biomarkers which help in treatment selection. Results: We identified 3640 number of hits of which 58 articles were found to be relevant. Here we addressed biomarkers in the context of prognosis, prediction and patient selection of therapy. These biomarkers were found to be effective as prognostic or predictive factors under variety of conditions. The higher levels for all these biomarkers were associated with shorter median OS and sometimes PFS. Lower amounts of biomarkers in serum or urine were associated with prolonged survival outcomes, longer time to CRPC development or CRPC progression and longer median follow-up irrespective of any therapy. Conclusion: We observed that the biomarkers included in our study predicted clinically relevant survival outcomes and treatment exposure. Though the current biomarkers are prognostic when measured prior to initiating treatment, not all are validated as predictive markers in post treatment setting. A greater understanding of biomarkers in CRPC is need of the hour for development of more personalized approach to maximize benefit and minimize harm in men with CRPC.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several CRPC cohorts reported a low Hb level as an OS prognostic factor, both for patients receiving any treatment 9 , and for patients who received chemotherapy 11 , 18 . However, a subanalysis of the impact of low Hb levels in patients who did not receive chemotherapy has not been conducted previously.…”

Section: Discussionmentioning

confidence: 99%

“…In mCRPC patients who received these new therapeutic agents, many prognostic factors of OS have been identified. Such factors include liver metastasis 16 , PS 16 , duration of ADT treatment 16 , time from prostate cancer diagnosis 17 , presence of pain 17 , PSA 18 , 19 , LDH 16 , 17 , Alb 16 , ALP 17 , Hb 18 , cycles of chemotherapy 18 , response to prior chemotherapy 18 , PSA decline after CRPC treatment 20 , 21 , age 19 , GS 19 , nadir PSA 22 , and time to nadir PSA (TNPSA) 22 .…”

Section: Introductionmentioning

confidence: 99%

“…Among these cohorts, some prognostic factors can only be obtained after CRPC treatment, such as cycles of chemotherapy, response to chemotherapy, and PSA decline after CRPC treatment 11 , 12 , 18 , 20 , 21 . Although these factors might reflect OS well, we cannot apply these factors for the OS prediction or treatment decision-making at the time of CRPC diagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients

Hakozaki

Yamada

Takeshima

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The objective of this study was to identify the prognostic factors and to propose a new risk model in metastatic castration-resistant prostate cancer (mCRPC) patients. The clinical data were retrospectively obtained for 102 mCRPC patients who received cancer treatment between 2005 and 2018 at the University of Tokyo Hospital. We investigated clinical and pathological parameters, including prostate-specific antigen (PSA) kinetic profiles under androgen deprivation treatment, and identified predictors of overall survival (OS). The median age and PSA were 73 (Interquartile range [IQR], 68–79) years and 5.00 (IQR, 2.77–13.6) ng/ml. The median follow-up was 34 (IQR, 17–56) months. In univariate analysis, ‘lymph node metastasis’, ‘Hemoglobin (Hb)’, ‘Time to nadir PSA (TNPSA)’, ‘PSA doubling time (PSADT)’, ‘Time to CRPC’, and ‘presence of pain’ were prognostic factors. Multivariate analysis identified ‘Hb < 11 g/dL’, ‘TNPSA < 7 months’ and ‘PSADT < 5 months’ as independent prognostic factors of OS. The high-risk group (patients with two or three factors) demonstrated shorter OS (23 vs. 50 months) with an increased risk of death (HR = 2.997; 95% CI 1.632–5.506; P = 0.0004). The proposed risk stratification model may contribute to the prediction of survival and provide supportive information in treatment decision-making.

show abstract

“…In the phase III TROPIC trial, cabazitaxel plus prednisone demonstrated significant antitumor activity and improved overall survival (OS) and disease progression during or after docetaxel-based therapy in patients with metastatic CRPC (9). However, in real-world clinical practice, there is limited information on the efficacy, adverse events, and prognostic factors associated with use of cabazitaxel (10)(11)(12)(13)(14)(15)(16). In the present study, we retrospectively evaluated the efficacy, adverse events and prognostic factors associated with cabazitaxel in patients with CRPC after chemotherapy.…”

mentioning

confidence: 99%

Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy

Iwamoto

Kano

Shimada

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background/Aim: Cabazitaxel is recommended as first-line treatment after docetaxel for metastatic castrationresistant prostate cancer. However, the efficacy, adverse events and prognostic factors associated with cabazitaxel are unclear. Patients and Methods: This single-centre retrospective study including 30 patients with CRPC treated with cabazitaxel between 2014 and 2020 investigated efficacy, outcomes and prognostic factors. Results: Fourteen patients had visceral metastases. The median cabazitaxel dose was 20 mg/m 2 . The prostate-specific antigen response rate, time to prostate-specific antigen response, and overall survival were 13.3%, 3.48 months, and 7.92 months, respectively. The rates of grade 3 or more neutropenia and febrile neutropenia were 20% and 6.7%, respectively. By multivariate analysis, sarcopenia and visceral metastasis at the time of cabazitaxel initiation were independent and significant factors conferring a poor prognosis. Conclusion: The early introduction of cabazitaxel, prior to the development of sarcopenia and visceral metastasis, might contribute to improved prognosis in CRPC. Prostate cancer (PC), the most common cancer in males, is a leading cause of cancer-related deaths in developed countries (1, 2). The development and widespread use of prostate-1703 This article is freely accessible online.

show abstract

Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan

Cited by 8 publications

References 0 publications

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients

Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy

Contact Info

Product

Resources

About